GleamWall
中文EN

PCRX Pacira BioSciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1396814 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.7%
TTM net income YoY76.0%
TTM EPS YoY97.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR75.5%

Margins

Gross margin78.7%
Operating margin4.8%
Net margin5.1%
FCF margin22.7%
EBITDA margin12.4%

Returns

ROE5.2%
ROA3.0%
ROIC (approx.)4.2%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets40.8%
Debt / equity0.41x
Current ratio4.68x
Interest coverage2.54x

Cash quality & payout

Operating cash flow / net income4.69x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$176.65M$192.40M$177.38M$196.87M$179.52M$181.10M$168.92M$187.25M
Cost of revenue$37.23M$44.16M$36.41M$40.30M$34.28M$40.87M$34.31M$39.89M
Gross profit$139.42M$148.24M$140.96M$156.57M$145.24M$140.23M$134.62M$147.37M
R&D expense$26.68M$30.24M$28.07M$37.45M$25.97M$28.20M$25.34M$23.90M
SG&A expense$83.84M$91.81M$93.94M$101.61M$91.80M$88.58M$86.78M$79.61M
Operating income$22.27M$4.27M$6.90M$2.34M$6.36M$8.50M$1.99M$24.70M
Interest expense$2.88M$3.62M$3.70M$3.89M$4.28M$4.70M$4.58M$4.68M
Pretax income$28.81M$2.56M$5.00M$571,000$9.52M-$1.93M$8.71M$25.53M
Income tax$293,000-$2.10M$2.08M-$1.07M$4.09M$2.92M$3.89M$9.48M
Net income$28.52M$4.65M$2.92M$1.64M$5.43M-$4.85M$4.81M$16.04M
EBITDA$29.17M$11.27M$28.23M$23.68M$13.26M$21.50M$23.16M$45.95M
EPS (basic)0.720.120.07—0.12-0.110.10—
EPS (diluted)0.700.120.07—0.12-0.110.10—
Weighted avg. shares (diluted)40.83M40.30M40.91M—44.46M45.46M46.53M—
Balance sheet
Cash & equivalents$246.96M$205.88M$144.31M$158.54M$147.59M$300.48M$283.61M$276.77M
Short-term investments$48.62M$45.16M$57.87M$79.88M$98.75M$145.38M$210.02M$207.84M
Receivables$122.89M$132.42M$125.64M$124.07M$115.27M$114.37M$104.75M$113.30M
Inventory$129.49M$134.57M$150.37M$152.86M$157.68M$148.16M$133.75M$125.28M
Current assets$590.23M$615.22M$514.96M$547.97M$562.75M$745.61M$759.96M$745.13M
PP&E, net$129.18M$130.28M$136.28M$140.69M$147.39M$155.18M$164.45M$167.17M
Goodwill$19.54M$19.64M$19.77M$20.21M$20.32M$20.30M$21.52M$0
Intangibles$273.00M$285.48M$353.23M$368.10M$382.40M$422.56M$434.97M$425.97M
Total assets$1.20B$1.24B$1.21B$1.26B$1.30B$1.54B$1.59B$1.55B
Current liabilities$126.10M$122.01M$108.79M$120.59M$107.08M$313.16M$314.73M$309.92M
Short-term debt———$0$0——$201.78M
Long-term debt$293.59M$363.12M$367.66M$372.19M$376.72M$580.49M$583.38M$383.55M
Total debt$293.59M$363.12M$367.66M$372.19M$376.72M$580.49M$583.38M$585.32M
Total liabilities$490.32M$572.00M$554.64M$571.81M$570.36M$779.50M$788.13M$775.17M
Shareholders' equity$712.32M$671.98M$653.89M$693.11M$727.21M$757.77M$798.54M$778.35M
Net debt$46.63M$157.25M$223.35M$213.64M$229.13M$280.01M$299.77M$308.55M
Shares outstanding39.90M39.82M39.31M41.12M42.97M44.90M46.28M46.24M
Cash flow statement
Operating cash flow$50.07M$57.46M$25.68M$43.69M$60.83M$12.01M$35.46M$33.13M
Capital expenditure$3.62M$1.34M$2.72M$218,000$3.87M$2.70M$8.55M$2.12M
Free cash flow$46.45M$56.12M$22.96M$43.47M$56.96M$9.31M$26.91M$31.01M
Investing cash flow$60.81M$11.76M$19.44M$19.33M$43.61M$62.16M-$25.63M-$368,000
Financing cash flow-$69.77M-$7.65M-$59.40M-$51.65M-$257.48M-$57.51M-$2.99M-$1.96M
Depreciation & amortization$6.90M$7.00M$21.33M$21.34M$6.90M$13.00M$21.17M$21.24M
Stock-based compensation$11.82M$14.96M$13.54M$13.50M$13.98M$15.47M$14.55M$12.27M
Share buybacks$0$0$50.05M$48.25M$50.04M$50.04M$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.